Cosmos Health, an international healthcare group headquartered in Thessaloniki, Greece, focuses on nutraceuticals, pharmaceuticals, and healthcare distribution. The third-quarter 2026 results stand out because they arrive at a time when management aims to demonstrate that strong revenue growth can lead to sustainable margin expansion and a more stable balance sheet. Earlier periods showed solid top-line increases that were tempered by gross margin pressure and non-cash charges linked to financing and digital-asset positions. Given the company’s going-concern note and dependence on external funding, investors are monitoring whether better margins, lower debt, and rising subscription revenue point to a real turning point.
For the first nine months of 2026, COSM recorded revenue of $53.59 million, representing a 17.6% increase from $45.57 million in the same period last year. The third quarter featured notable margin progress, with gross margin rising to 12.6%, up 465 basis points from 7.96% in the second quarter. Adjusted EBITDA advanced about 18% sequentially, and the net loss narrowed compared with the prior year.
The balance sheet showed clear improvement. Total debt fell 34% from year-end after the company settled the full $8.0 million ATW convertible note before maturity. Total liabilities declined 18.2% from the end of 2025, while stockholders’ equity increased 21.2% to $22.33 million—its third consecutive quarterly rise—lowering the debt-to-equity ratio to 0.57x from 1.05x. Working capital improved to $2.34 million from $0.12 million at December 31, 2025.
On the operational side, U.S. direct-to-consumer subscriptions exceeded 12,500 active accounts, generating roughly $1.83 million in monthly subscription value, or about $22 million annualized. The contract manufacturing pipeline reached a record 32.7 million units. Under its $5 million share repurchase program, the company acquired 123,100 shares in the quarter for approximately $630,000, bringing cumulative repurchases to 255,600 shares for about $1.15 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Shares moved higher in pre-market trading following the release, as attention centered on the pronounced gross-margin rebound and the reduction in leverage. The narrowing net loss, third straight quarter of equity growth, and continued growth in U.S. subscriptions suggest that operational improvements may be taking hold. At the same time, investor caution persists due to ongoing reliance on external financing and exposure to digital-asset volatility, both of which have affected prior results. Whether the margin recovery and subscription momentum prove lasting will likely shape sentiment in the sessions ahead.
Several areas merit close attention after this report. The path of gross margin remains central; the 465-basis-point sequential gain points to a more favorable product mix or efficiency gains, so management’s guidance on sustainability will be telling. The U.S. subscription segment also warrants tracking, given more than 12,500 active accounts and roughly $22 million in annualized value—the pace of additions and retention will indicate whether this can develop into a consistent, higher-margin revenue source.
Balance-sheet trends matter as well. Settlement of the ATW note and lower overall debt have eased leverage, yet the going-concern qualification and need for external capital remain. Cash levels, working capital, and any new financing will be worth following. Finally, the record 32.7 million unit contract manufacturing pipeline and new automated order-processing capabilities in Athens could support higher volumes in the fourth quarter. Cost patterns, digital-asset adjustments, and currency movements are other variables that have influenced results historically.
In my analysis of names like COSM, I often turn to Tickeron’s AI Screener to quickly filter opportunities across healthcare and consumer sectors using technical patterns, fundamentals, and AI signals. It helps surface relevant setups more efficiently than manual checks and supports ongoing monitoring of margin and growth trends.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
COSM saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 85 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for COSM turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 39 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
COSM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COSM crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for COSM entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where COSM's RSI Indicator exited the oversold zone, 38 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for COSM moved above the 200-day moving average on November 05, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +18.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where COSM advanced for three days, in 192 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
COSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (14.423). P/E Ratio (-0.455) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.850) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (4.260).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. COSM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COSM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors